American CryoStem to Study New Standardized Treatment Protocols for Wound Healing

November 16, 2021 1:00 AM

EATONTOWN, NJ / ACCESSWIRE / November 16, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has completed the development of a new standardized wound healing protocol utilizing its tissue based technologies with Advanced Regenerative Associates (Tinton Falls, NJ). The Company's wound healing...

Read more

Helix BioPharma Corp. Provides Second Bi-Weekly MCTO Status Update

November 15, 2021 6:15 PM

RICHMOND HILL, ON / ACCESSWIRE / November 15, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is providing this bi-weekly update on the status of the management cease trade order granted on November 1, 2021 (the "MCTO") by its principal regulator, the Ontario Securities Commission under National Policy 12-203 Management...

Read more

Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 15, 2021 4:01 PM

- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis -- Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market -- Topline results from DMT410 POC study in multiple aesthetic skin conditions to be presented November 19, 2021 -- On track to initiate DMT310 Phase 2 study for moderate-to-severe rosacea in Q4 2021 -SAN DIEGO, CA / ACCESSWIRE / November 15, 2021 /...

Read more

RedHill Biopharma Ltd Announces RedHill: LPI in Part A of RHB-107 P2/3 COVID Study

November 15, 2021 7:02 AM

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized PatientsRecruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital careTop-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose...

Read more

Apollo Endosurgery to Present at Four Upcoming Investor Conferences

November 12, 2021 9:00 AM

AUSTIN, TX / ACCESSWIRE / November 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that management will participate in four upcoming investor conference events.Conferences Apollo Endosurgery management will participate include:Monday, November 15, 2021Stifel 2021 Healthcare Conference (Virtual)Management will lead a...

Read more

EV Biologics Updates on NFT Dividend

November 12, 2021 8:45 AM

NASHVILLE, TN / ACCESSWIRE / November 12, 2021 / EV Biologics Corp, (OTC PINK:YECO), today updated shareholders with further details about its NFT dividend.The Company is still awaiting approval from FINRA for the distribution of the dividend. This is the first time that any public company has attempted to distribute a NFT digital asset as a dividend. As soon as FINRA approves the distribution of the dividend, the Company will issue the NFT to...

Read more

Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting

November 12, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / November 12, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced details regarding the presentation of efficacy and safety results for its Phase 1b proof of concept study evaluating a single application of DMT410 to treat multiple aesthetic skin conditions."A Study of...

Read more

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

November 12, 2021 8:00 AM

Company advancing XCARTTM pre-clinical development plan toward IND-enabling studiesStrengthened cash position to fund operations through XCART IND filing with recently completed $12.5 million private placementContinued royalty stream growth through license agreement with PolyXen® platform technologyFRAMINGHAM, MA / ACCESSWIRE / November 12, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical...

Read more

American CryoStem Enters into an Agreement to Exchange Shares held by ACS Global, Inc

November 12, 2021 1:00 AM

EATONTOWN, NJ / ACCESSWIRE / November 12, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading strategic cellular application developer, global licensor of patented adipose tissue-based technologies for the Regenerative and Personalized Medicine industries, today announced an agreement has been reached between the Company and ACS Global, Inc to exchange 20,000,000 million CRYO common shares currently held by ACS Global, Inc for...

Read more

Applied UV to Host Third Quarter 2021 Conference Call on November 16th

November 11, 2021 11:35 AM

MOUNT VERNON, NY / ACCESSWIRE / November 11, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that the Company will be hosting an investor conference call and live webcast...

Read more

Black Bird Biotech Offers Thanks to All Veterans and Their Families

November 11, 2021 10:10 AM

Black Bird Biotech Offers Thanks to All Veterans and Their FamiliesFLOWER MOUND, TX / ACCESSWIRE / November 11, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT) released the following statement:On this Veterans Day, the Black Bird Biotech team offers our heart-felt thanks to all of our Great Veterans for their service of our country, and for embodying every quality that makes our country the greatest in human history. We also remember those who...

Read more

Viewpoint Molecular Targeting(R) to Present at the Virtual Investor Roundtable Event

November 11, 2021 10:00 AM

Live moderated video webcast discussion among members of Viewpoint Management and Thought Leaders Oliver Sartor MD, Geoffrey B. Johnson MD, PhD, Vikas Prasad MD, on Thursday, November 18th at 1:00 PM ETCORALVILLE, IA / ACCESSWIRE / November 11, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary...

Read more

EV Biologics Signs Listing Agreement With INX

November 11, 2021 9:15 AM

NASHVILLE, TN / ACCESSWIRE / November 11, 2021 / EV Biologics Corp, ("the Company"), OTC PINK:YECO, today confirmed that it has signed an agreement to list its common stock on the INX Securities ATS, a regulated alternative trading system operated by INX Securities, LLC. INX Securities, LLC is the FINRA-member broker-dealer subsidiary of INX Limited.The Company has completed its due diligence and has been approved to list on the INX Securities...

Read more

Pressure BioSciences Awarded Second U.S. Patent for Its Revolutionary Ultra Shear Technology Platform, for Its Innovative NanoGap Valve

November 11, 2021 8:10 AM

Dynamically-Adaptive Compact Valve is Key Component in the Company's Highly Anticipated and Proprietary UST Platform; UST Expected to Help Deliver Strong Sales Growth and Profitability in 2022SOUTH EASTON, MA / ACCESSWIRE / November 11, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialized services to the...

Read more

Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

November 11, 2021 8:05 AM

BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:Jefferies London Healthcare ConferenceThursday, November...

Read more

enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 11, 2021 8:05 AM

- Quarter marked by corporate rebranding and strategic prioritization of development programs- Company executing on SAVVE U.S pivotal trial evaluating lead product, the VenoValve®, as a potential treatment for severe deep venous Chronic Venous Insufficiency (CVI)- Bolstered cash position with recently completed $20 million registered direct offering with leading life sciences investment firmIRVINE, CA / ACCESSWIRE / November 11, 2021 /...

Read more

Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions

November 11, 2021 6:00 AM

SAN DIEGO, CA / ACCESSWIRE / November 11, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will host a virtual investor event to present the DMT410 Phase 1b results in multiple aesthetic skin conditions on Friday, November 19, 2021 at 4:30 pm ET.The virtual investor event will feature a...

Read more

Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes

November 10, 2021 9:00 AM

KELOWNA, BC / ACCESSWIRE / November 10, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for several new and ongoing DehydraTECHTM applied R&D programs for 2022. The studies mentioned herein are only a fraction of Lexaria's 2022 work programs."Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for...

Read more

Black Bird Biotech Provides Corporate Update, Following Completion of Funding Round and Repayment of Convertible Debt

November 10, 2021 8:50 AM

FLOWER MOUND, TX / ACCESSWIRE / November 10, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today updated its current status and ongoing progress, following the completion of its current Regulation A funding round. With a portion of the offering proceeds, the company has repaid approximately $700,000 in convertible debt instruments, leaving nearly $1 million available for immediate...

Read more

BioInvent and Transgene present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021

November 9, 2021 8:20 AM

LUND, SE / ACCESSWIRE / November 9, 2021 / BioInvent International (STO:BINV)Data support BT-001's unique dual mode of actionBioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based...

Read more